Scientific article
Open access

Management of hepatocellular carcinoma: SASL expert opinion statement

Published inSwiss Medical Weekly, vol. 150, w20296
Publication date2020

Hepatocellular carcinoma (HCC) is the most frequent primary malignancy of the liver. HCC is characterised by a heterogeneous clinical presentation. Liver cirrhosis is the most important risk factor for HCC. Regular surveillance with ultrasound examinations allows detection of HCC at an early stage, where curative treatment options such as surgical resection, liver transplantation and local ablative therapies can be applied. More advanced tumours are treated with transarterial chemo- or radiotherapy, and with systemic treatments including immunotherapies. Treatment decisions are based on tumour staging and liver function, and should be made in specialised interdisciplinary tumour boards. This expert opinion statement by the Swiss Association for the Study of the Liver reviews the current state of HCC management and provides recommendations adapted to the health care environment in Switzerland.

  • Liver cancer
  • Hepatocellular carcinoma
  • Antineoplastic agents
  • Liver surgery
  • Patient selection
Citation (ISO format)
GOOSSENS, Nicolas, TOSO, Christian, HEIM, Markus H. Management of hepatocellular carcinoma: SASL expert opinion statement. In: Swiss Medical Weekly, 2020, vol. 150, p. w20296. doi: 10.4414/smw.2020.20296
Main files (1)
Article (Published version)
ISSN of the journal1424-7860

Technical informations

Creation08/27/2020 4:29:00 PM
First validation08/27/2020 4:29:00 PM
Update time03/15/2023 10:42:11 PM
Status update03/15/2023 10:42:11 PM
Last indexation02/12/2024 1:18:54 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack